An exploratory study of a multi-species probiotic formulation and markers of health in a real-world oncological cohort in the time of covid.
- 2024-06-26
- Clinical Trial
- Inflammopharmacology 32(4)
- Michael Thomsen
- Ravichandra Vemuri
- Flavia Huygens
- Stephen Clarke
- Luis Vitetta
- PubMed: 38926298
- DOI: 10.1007/s10787-024-01503-1
- Moderate evidence
No significant changes in microbiota alpha- and beta-diversity at the phylum and species levels respectively from baseline to end of study treatment was observed.
- Effect
- Beneficial
- Effect size
- Small
- Significant
- No